ArticleMammalian genome : official journal of the International Mammalian Genome Society2026
Multi-omics analysis of HLTF context-dependent regulation across TCGA cohorts revealed its potential as new biomarker in tumour.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SNF2-family Helicase-Like Transcription Factor (HLTF) has been implicated in tumorigenesis, with evidence suggesting both tumour-suppressive and oncogenic functions. To clarify the nature of this increasingly emerging double function, we analysed the full HLTF's alterome across TCGA cohorts combining first gene expression with genomic and epigenomic layers of de-regulation, and investigating further their determinants through the integration of DNA methylation profiles - both at promoter-proximal and distal regions, the copy-number alterations, and all somatic mutations. This multi-layered analysis highlighted specific context-dependent HLTF's regulatory configurations across human cancers, even modulated by either dosage effects or loss-of-function events. The clinical relevance of HLTF's alterations, identified through tumour-specific associations with patient outcomes, supports its potential as new biomarker in cancer overall.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.